Ultragenyx Pharmaceutical (RARE) Change in Cash (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has reported Change in Cash for 14 consecutive years, with -$247.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Cash fell 448.89% year-over-year to -$247.0 million; the TTM figure through Mar 2026 stood at $50.0 million (up 193.62% YoY), while the FY2025 annual figure was $252.0 million, up 820.0% from the prior year.
• Change in Cash retreated to -$247.0 million in Q1 2026 per RARE's latest filing, from $221.5 million in the prior quarter.
• Across five years, Change in Cash topped out at $367.9 million in Q2 2024 and bottomed at -$330.0 million in Q3 2024.
• Historically, Change in Cash has averaged -$7.1 million across 5 years, with a median of $6.5 million in 2022.
• On a YoY basis, Change in Cash climbed as much as 2179.24% in 2024 and fell as far as 1035.71% in 2024.
• Ultragenyx Pharmaceutical's Change in Cash stood at -$258.7 million in 2022, then jumped by 154.11% to $140.0 million in 2023, then tumbled by 82.72% to $24.2 million in 2024, then surged by 815.69% to $221.5 million in 2025, then slumped by 211.53% to -$247.0 million in 2026.
• Business Quant data shows RARE's Change in Cash at -$247.0 million in Q1 2026, $221.5 million in Q4 2025, and $26.1 million in Q3 2025.